Literature DB >> 18433609

Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.

Steven M Horwitz1, Elise A Olsen, Madeleine Duvic, Pierliugi Porcu, Youn H Kim.   

Abstract

The NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Disease were recently revised to include recommendations for treating mycosis fungoides and Sézary syndrome. These uncommon lymphomas require a specialized evaluation and use a unique TNMB staging system. Unlike the other forms of non-Hodgkin's lymphomas, stage overwhelmingly determines prognosis and defines radically different treatment approaches. For patients with early-stage disease, initial treatment with skin-directed therapies is preferred, and many patients never require systemic therapy. For patients with refractory or advanced-stage disease, biologic therapies are often the first choices, whereas chemotherapies are reserved for later in the disease course. Many milder therapies may be repeated several times in the disease course, and maintenance and tapering strategies are common. This article also discusses the emerging role of allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433609     DOI: 10.6004/jnccn.2008.0033

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  23 in total

Review 1.  New targets of therapy in T-cell lymphomas.

Authors:  Jack Erter; Lapo Alinari; Kamruz Darabi; Metin Gurcan; Ramiro Garzon; Guido Marcucci; Mark A Bechtel; Henry Wong; Pierluigi Porcu
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

Review 2.  Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.

Authors:  Louise Photiou; Carrie van der Weyden; Christopher McCormack; H Miles Prince
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

3.  In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

Authors:  Youn H Kim; Dita Gratzinger; Cameron Harrison; Joshua D Brody; Debra K Czerwinski; Weiyun Z Ai; Anjali Morales; Farah Abdulla; Leon Xing; Daniel Navi; Robert J Tibshirani; Ranjana H Advani; Bharathi Lingala; Sumit Shah; Richard T Hoppe; Ronald Levy
Journal:  Blood       Date:  2011-11-01       Impact factor: 22.113

4.  Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.

Authors:  Robin Frye; Mary Myers; Karen C Axelrod; Elizabeth A Ness; Richard L Piekarz; Susan E Bates; Susan Booher
Journal:  Clin J Oncol Nurs       Date:  2012-04       Impact factor: 1.027

Review 5.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Authors:  A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

6.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Authors:  Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

7.  Cutaneous T-cell lymphoma in sub-Saharan Africa.

Authors:  Matthew Ulrickson; Fred Okuku; Victoria Walusansa; Oliver Press; Sam Kalungi; David Wu; Fred Kambugu; Corey Casper; Jackson Orem
Journal:  J Natl Compr Canc Netw       Date:  2013-03-01       Impact factor: 11.908

Review 8.  Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

Authors:  Max Schlaak; Juliane Pickenhain; Sebastian Theurich; Nicole Skoetz; Michael von Bergwelt-Baildon; Peter Kurschat
Journal:  Cochrane Database Syst Rev       Date:  2013-08-29

9.  Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.

Authors:  Madeleine Duvic; Michael T Tetzlaff; Pamela Gangar; Audra L Clos; Dawen Sui; Rakhshandra Talpur
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

Review 10.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.